Solvay cuts 2026 profit outlook as Saudi peroxide shutdown and Middle East conflict pressure cash flow

Solvay SA (Euronext Brussels: SOLB) has lowered its 2026 earnings and cash flow guidance after disruptions linked to the Middle East conflict and the continued shutdown of a peroxide plant at the Sadara complex in Jubail, Saudi Arabia. The Belgian chemicals manufacturer now expects full-year underlying EBITDA of €720 million to €740 million, down from its previous forecast of €770 million to €850 million. Free cash flow to shareholders from continuing operations is expected to reach €120 million to €150 million, compared with management’s earlier expectation of at least €200 million. The downgrade follows preliminary third-quarter underlying EBITDA of €173 million and places greater pressure on Solvay’s ability to protect industrial profitability while maintaining investment and restructuring commitments.

The October 19, 2026 update revealed that regional disruptions reduced third-quarter underlying EBITDA by approximately €25 million, including nearly €15 million attributed to the continued shutdown of the Sadara peroxide plant. The conflict had already reduced EBITDA by approximately €20 million in the second quarter, bringing the identified impact across the two quarters to around €45 million. Solvay is exploring contractual mechanisms within its Sadara joint venture that could potentially recover some lost profitability, although no recovery has been confirmed. The reduced outlook excludes possible revenue or recovery measures associated with Sadara for the remainder of 2026, meaning the eventual financial contribution will depend partly on operational developments and the application of contractual provisions.

Why has Solvay reduced its 2026 EBITDA guidance despite relatively stable third-quarter sales?

Solvay reported preliminary third-quarter underlying net sales of €1.03 billion, broadly consistent with the €1.031 billion reported in the second quarter. However, underlying EBITDA declined from €187 million in the preceding quarter to €173 million, indicating that relatively stable revenue did not translate into stable profitability. The implied underlying EBITDA margin was approximately 16.8%, compared with 18.1% in the second quarter. The weaker margin reflects the company’s exposure to operating disruptions and the difficulty of absorbing fixed costs when parts of its production network are unavailable.

The new full-year forecast represents a meaningful reset of management expectations. At the midpoint, underlying EBITDA guidance has fallen from €810 million to €730 million, a reduction of approximately 9.9%. The revised range is also narrower, suggesting that management has updated its expectations using the latest available operating information rather than maintaining the previous recovery scenario. The lower guidance is especially consequential because Solvay had reiterated its earlier target in July while anticipating a restart of the Saudi peroxide operation during the third quarter.

The latest figures indicate that the anticipated restart did not occur on the timetable embedded in the previous outlook. The plant’s continued closure has affected production volumes and earnings from the relevant joint venture activities, while the broader regional conflict has generated additional operational consequences. Solvay has not described the shutdown as a permanent closure of its Saudi activities or as a suspension of the entire chemicals group. The financial exposure identified in its preliminary results relates to specific regional operations and associated business effects.

How important is the Sadara peroxide facility in Jubail to Solvay’s chemicals earnings?

Solvay’s Saudi operations are conducted through a joint venture with Sadara, an industrial chemicals venture majority-owned by Saudi Aramco. The peroxide facility forms part of Solvay’s broader Peroxides business, which supplies industrial applications requiring specialised chemical processing. The operation has been temporarily shut since March 2026, according to Solvay’s previous quarterly disclosures. Its continued unavailability has reduced the earnings contribution that management expected from the relevant production activities.

The effects can be separated into two periods. Solvay identified approximately €20 million of EBITDA pressure from the Middle East conflict during the second quarter and an additional €25 million during the third quarter. The third-quarter impact included nearly €15 million associated specifically with the plant shutdown, leaving other regional consequences within the broader quarterly estimate. These figures demonstrate that the disturbance has continued beyond the initial operating interruption and has affected the company’s ability to meet its annual targets.

The commercial importance of peroxide operations was already visible in Solvay’s second-quarter disclosures. Peroxides sales fell approximately 3.5% year over year to €218 million, with the Saudi shutdown contributing to lower volumes. Demand for certain electronic-grade products remained stronger, indicating that weakness was not uniform across the entire product portfolio. Nevertheless, reduced production from the affected plant constrained the segment’s ability to benefit from demand in other applications.

Solvay has indicated that the joint venture agreement contains contractual mechanisms designed to address lost profitability. Whether those mechanisms ultimately provide financial recovery will depend on the relevant contractual conditions and subsequent developments. The company has not disclosed a confirmed compensation amount, an agreed payment timetable or a final settlement. Any potential recovery should therefore remain separate from earnings already reported and from the revised annual forecast.

Does Solvay’s lower free cash flow guidance signal a broader balance-sheet challenge?

The cash flow downgrade is potentially as important as the EBITDA reduction because Solvay continues to fund industrial operations, capital expenditure and transformation activities. Management now expects free cash flow to shareholders from continuing operations of €120 million to €150 million, net of approximately €90 million in transformation expenses. Previously, it expected at least €200 million of free cash flow under the same broad reporting definition. The new upper end is therefore €50 million below the earlier minimum expectation.

Preliminary third-quarter free cash flow reached €54 million, compared with an outflow of €11 million in the second quarter. The improvement reflects a stronger quarterly cash contribution, although first-half free cash flow had reached only €15 million. Combining the first-half reported figure with preliminary third-quarter cash flow produces approximately €69 million for the first nine months. The updated annual guidance therefore implies that Solvay would need to generate approximately €51 million to €81 million in the fourth quarter to meet its revised target, assuming the reported definitions remain consistent.

The company’s balance sheet provides additional context. At June 30, 2026, underlying net financial debt stood at approximately €1.83 billion, while the underlying leverage ratio was 2.3 times EBITDA. Lower full-year earnings and cash generation could limit the pace of debt reduction if other balance-sheet factors remain unchanged. However, the October 19 preliminary release did not provide a complete updated third-quarter debt position, so a precise current leverage calculation would require the forthcoming financial statements.

Solvay’s financial flexibility also depends on its industrial investment programme. Earlier guidance included capital expenditure of approximately €300 million for 2026, alongside continued spending on operational improvements and strategic projects. These commitments are intended to protect competitiveness and support future growth, but they create demands on cash generation during a period of earnings pressure. The reduced guidance increases the importance of working-capital discipline and the financial returns generated by existing investment projects.

Can Solvay’s cost-saving programme offset pressure in soda ash, peroxides and specialty chemicals?

Solvay has been pursuing a transformation programme aimed at reducing structural costs and improving industrial efficiency. During the second quarter, its initiatives delivered approximately €26 million in additional structural savings, principally through manufacturing improvements. The company previously targeted cumulative structural cost savings of approximately €300 million by the end of 2026. Its October 19 update reiterated its commitment to transformation and cash generation, although it did not provide a revised quantified cost-saving target.

The savings programme operates alongside challenging market conditions in several chemical businesses. Solvay’s second-quarter underlying sales declined 7.4% organically, reflecting lower volumes and weaker pricing, particularly in certain soda ash markets. Soda Ash and Derivatives revenue fell approximately 8.6%, while Performance Chemicals sales decreased approximately 5.7%. These developments indicate that the Saudi shutdown is not the only influence on the group’s operating performance.

The decline in soda ash pricing creates a separate earnings challenge because the chemical is used across glassmaking and other industrial applications. Weakness in seaborne pricing can reduce margins even when manufacturing plants continue operating normally. Meanwhile, lower volumes across certain specialty chemical activities constrain fixed-cost absorption. Solvay therefore needs both operating cost discipline and improved commercial conditions to restore underlying margins.

Some businesses have shown greater resilience. The company previously reported improved pricing in parts of its Coatis product portfolio, while demand for electronic-grade peroxides provided a positive counterweight to weaker industrial volumes. These variations suggest that Solvay’s profitability outlook should be evaluated across product categories rather than attributed entirely to one operating disruption. A sustained recovery would require the benefits from cost savings and stronger product lines to outweigh weaker pricing and disrupted capacity.

What does Solvay’s updated forecast imply for fourth-quarter earnings and its November results?

Solvay recorded underlying EBITDA of €406 million in the first half of 2026 and preliminary EBITDA of €173 million in the third quarter. Taken together, those figures indicate approximately €579 million of underlying EBITDA during the first nine months. The revised full-year forecast of €720 million to €740 million consequently implies fourth-quarter underlying EBITDA of approximately €141 million to €161 million. This calculation is based on the company’s disclosed figures and assumes no material changes during finalisation of the preliminary quarter.

The implied fourth-quarter range is below the €173 million reported for the third quarter, suggesting management is not building a rapid profitability rebound into the revised annual guidance. That may reflect continued uncertainty around Saudi operations, weaker chemical market conditions or other operating assumptions already incorporated into the updated outlook. The company has not provided a detailed breakdown explaining every component of the implied fourth-quarter movement. A precise assessment will require its complete third-quarter financial report and any accompanying management commentary.

Solvay is scheduled to publish its full third-quarter results on November 4, 2026. The release should provide more detailed information about divisional performance, working capital, net debt and the contribution of ongoing efficiency initiatives. It may also clarify whether any progress has been made toward restoring production at the Saudi facility. The difference between a sustained industrial disruption and a recoverable interruption remains commercially relevant because it affects both future revenue capacity and potential compensation under the joint venture arrangements.

How has Solvay stock reacted to the guidance reduction, and what is the outlook for investor sentiment?

Solvay shares closed at approximately €24.90 in Brussels on October 19, down 1.11% from €25.18 in the preceding session. The stock traded within a reported 52-week range of approximately €23.54 to €29.16, leaving the latest price relatively close to the lower end of that range. The modest negative daily movement coincided with publication of the profit warning, although it should not be interpreted as a complete measure of the financial damage or a definitive assessment of management’s revised strategy. Investor expectations may already have incorporated some concern about the Saudi shutdown and subdued European chemicals demand.

The cautious case for Solvay centres on the combination of weaker earnings, lower free cash flow and uncertainty around regional operating disruptions. The more constructive interpretation focuses on the company’s established chemical manufacturing portfolio, ongoing cost savings and the possibility that disrupted operations could eventually resume or generate recoveries under contractual mechanisms. Neither outcome is assured, and the extent of any earnings recovery will depend on operating conditions beyond management’s direct control. The stock’s valuation may remain sensitive to evidence that free cash flow can improve without requiring further reductions in investment.

The November 4 results will provide the next substantial test. Confirmation of the preliminary figures, an updated balance sheet and greater clarity on Sadara could help distinguish temporary losses from a more persistent deterioration in profitability. Meeting the implied fourth-quarter EBITDA requirement of €141 million to €161 million would support the revised guidance, while additional disruption or weaker soda ash pricing could place further pressure on expectations. Solvay’s immediate priority is to demonstrate that cash generation and cost savings can support its balance sheet even before the Saudi operation returns to normal.

What are the key takeaways from Solvay’s 2026 profit warning and Saudi operations disruption?

• Solvay lowered its 2026 underlying EBITDA outlook to €720 million to €740 million.
• The previous guidance range was €770 million to €850 million.
• Full-year free cash flow guidance was reduced to €120 million to €150 million.
• Preliminary third-quarter sales reached €1.03 billion, with underlying EBITDA of €173 million.
• The Middle East conflict reduced third-quarter EBITDA by approximately €25 million.
• Nearly €15 million of that quarterly impact related to the Sadara peroxide plant shutdown.
• Identified regional earnings impacts totalled approximately €45 million across the second and third quarters.
• The company is evaluating contractual mechanisms that may allow recovery of some lost profitability.
• The revised annual guidance implies fourth-quarter EBITDA of approximately €141 million to €161 million.
• The November 4 results will clarify balance-sheet conditions and the latest operating position.